Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Set Alert for Commercial

Killing Targeted Bacteria With CRISPR Drugs Is SNIPR BIOME's Promise

SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.

Clinical Trials Infectious Diseases Gastrointestinal

Vasopharm Sees Path Forward For Traumatic Brain Injury Drug

Vasopharm’s ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma, suggesting a role for the compound in the condition.

Neurology Clinical Trials Research & Development

Companies

Set Alert for Companies

Latest From Companies

Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

Business Strategies Generic Drugs

The BioPharma Shares Rising On Omicron Hopes And Fears

Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.

Companies Coronavirus COVID-19

Vertex Secures Phase II Win In Rare Kidney Condition

The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.

Clinical Trials Renal

Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio

AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.

Companies Gene Therapy

GSK Poaches New Vaccines R&D Chief From Pfizer

Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.

Companies Coronavirus COVID-19

Abogen and Neurophth Lead China mRNA, Gene And Cell Therapy Funding Rush

Total of $571m raised in China from 10 venture capital and private equity funding deals betting heavily on mRNA and targeted oncology, as well as gene and cell therapies.

China Financing
See All

Deals

Set Alert for Deals

Latest From Deals

Novartis Will Co-Develop UCB’s Alpha-Syn Inhibitor For Parkinson’s

Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.

Deals Business Strategies

GSK Dives Into Neurology With £30m Oxford University Pact

After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.

Deals Neurology

Coronavirus Update: Lukewarm US Panel For Molnupiravir, Inovio, Bharat Look At Omicron

A US FDA review panel has given a lukewarm reception to molnupiravir, while Inovio is assessing its vaccine candidates against the new omicron variant, J&J nears a South African vaccine deal with Aspen, and South Korea brings in new COVID-19 measures. Meanwhile, Serum exports Novavax vaccine, Bharat looks at Covaxin in Omicron and Ocugen's Covaxin trial put on hold. 

Coronavirus COVID-19 Approvals

Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout

Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.

M & A Deals

Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

Tech Transfer Round-Up Deals

Nykode Enters New Phase With Regeneron Vaccine Pact

Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.

Vaccines Deals
See All

Strategy

Set Alert for Strategy

Latest From Strategy

ImmunoGen’s Mirvetuximab Confidence Justified With Ovarian Cancer Win

The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.

Clinical Trials Personalized Medicine

Facility To Make UK Self-Sufficient In Vaccines Rumored To Be Up For Sale

The VMIC has neither confirmed or denied to Scrip a report from the Financial Times that the project, which has received many millions of taxpayer money, is about to be sold off privately, with Oxford BioMedica mentioned as a potential bidder. 

Coronavirus COVID-19 Manufacturing

Cash Injection Puts Quell At Forefront Of Treg Therapy

The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.

Financing Liver & Hepatic

India’s 'Thousand Talents' Moment And Models To Shift Gears In R&D

Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?

India Research & Development

Chinese Firms Look Inward To Access Innovation

Two recent licensing deals involving Chinese firms underscore the record level of agreements being inked between innovative domestic biotechs and generic drug makers, at a time when corporate valuations and geopolitical tensions have made cross-border transactions harder to grab.

China Deals

Merck KGaA Highlights First In Class Five For 2025 Market Boom

From BTK inhibitors in multiple sclerosis to candidates aiding cancer cell death, Merck KGaA is focusing on its first-in-class pipeline which it expects to make a significant impact from 2025.

Companies Cancer
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

Business Strategies Commercial

Novo Nordisk Braced For China Insulin Scheme Impact

The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.

China Market Access

Pharma Will Need To Embrace More Inward-Looking China

The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.

China Market Access
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

US Biosimilars Strength Rides On The Wings Of Oncology Launches

Herceptin, Avastin and Rituxan biosimilars have achieved notable market penetration, outpacing other biosimilar launches and contributing to lower drug spending, according to a report from Amgen.

Biosimilars Pricing Strategies

Wet AMD Market Snapshot: A High-Growth Market Poised For Change

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

Ophthalmic Market Snapshot

BI/Lilly's Jardiance Enters US Heart Failure Market Fray

Boehringer Ingelheim and Eli Lilly have gained a US approval for their SGLT2 inhibitor empagliflozin in heart failure with reduced ejection fraction, which could be extended further in coming months to other types of heart failure, adding to the products competing in this previously neglected therapeutic area.

Approvals Cardiovascular
See All
UsernamePublicRestriction

Register